Mark Balbach

Recent Posts

Eurofins reports Q3 2019 revenues increased 22.3% year-on-year to EUR 1,167m vs. EUR 955m in Q3 2018.

Posted by Mark Balbach on Nov 5, 2019 8:00:00 AM

Eurofins Central Laboratory is a member of Eurofins BioPharma Services, a division of Eurofins Scientific, (hereinafter sometimes “Eurofins” or “the Group”). As a member of the Group, we are pleased to release to you our Q3 2019 earnings. Over the first nine months of 2019, total revenues grew 23.6% to EUR 3,335m vs. EUR 2,698m during the same period last year. Eurofins continues to express strong organic growth of 6.4% reported in Q3 2019. In Western Europe and North America, Eurofins BioPharma Services continued to perform exceptionally, with a double digit organic growth in Q3 2019 thanks to sustained, above market and overall growth as strategic outsourcing remains strong in the biopharmaceutical industry.

Read More

Tags: Central Laboratory, Quality, Results, Drug Development, Development, Science Education, BioPharma